Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
ARMC5-CUL3 E3 ligase targets full-length SREBF in adrenocortical tumors
Yosuke Okuno, Atsunori Fukuhara, Michio Otsuki, Iichiro Shimomura
Yosuke Okuno, Atsunori Fukuhara, Michio Otsuki, Iichiro Shimomura
View: Text | PDF
Research Article Endocrinology

ARMC5-CUL3 E3 ligase targets full-length SREBF in adrenocortical tumors

  • Text
  • PDF
Abstract

Inactivating mutations of ARMC5 are responsible for the development of bilateral macronodular adrenal hyperplasia (BMAH). Although ARMC5 inhibits adrenocortical tumor growth and is considered a tumor-suppressor gene, its molecular function is poorly understood. In this study, through biochemical purification using SREBF (SREBP) as bait, we identified the interaction between SREBF and ARMC5 through its Armadillo repeat. We also found that ARMC5 interacted with CUL3 through its BTB domain and underwent self-ubiquitination. ARMC5 colocalized with SREBF1 in the cytosol and induced proteasome-dependent degradation of full-length SREBF through ubiquitination. Introduction of missense mutations in Armadillo repeat of ARMC5 attenuated the interaction between SREBF, and introduction of mutations found in BMAH completely abolished its ability to degrade full-length SREBF. In H295R adrenocortical cells, silencing of ARMC5 increased full-length SREBFs and upregulated SREBF2 target genes. siARMC5-mediated cell growth was abrogated by simultaneous knockdown of SREBF2 in H295R cells. Our results demonstrate that ARMC5 was a substrate adaptor protein between full-length SREBF and CUL3-based E3 ligase, and they suggest the involvement of the SREBF pathway in the development of BMAH.

Authors

Yosuke Okuno, Atsunori Fukuhara, Michio Otsuki, Iichiro Shimomura

×

Figure 4

ARMC5 ubiquitinated and degraded full-length SREBF1.

Options: View larger image (or click on image) Download as PowerPoint
ARMC5 ubiquitinated and degraded full-length SREBF1.
(A) Western blottin...
(A) Western blotting of lysates from the HEK293T cells transfected with pcDNA3.1-FLAG-Srebf1 and pRK5-HA-Ubiquitin-WT, together with pcDNA3.1-myc (–), pcDNA3.1-myc-mArmc5 (WT), pcDNA3.1-myc-mArmc5ΔARM (ΔARM), or pcDNA3.1-myc-mArmc5ΔBTB (ΔBTB) for 24 hours with the indicated antibody. (B) Western blotting of lysates from the HEK293T cells transfected with pcDNA3.1-FLAG-Srebf1(N) and pRK5-HA-Ubiquitin-WT, together with pcDNA3.1-myc (–), pcDNA3.1-myc-mArmc5 (WT), pcDNA3.1-myc-mArmc5ΔARM (ΔARM), or pcDNA3.1-myc-mArmc5ΔBTB (ΔBTB) for 24 hours with the indicated antibody. (C) Western blotting of lysates from the HEK293T cells transfected with pcDNA3.1-FLAG-Srebf1 together with pcDNA3.1-myc (–) or pcDNA3.1-myc-mArmc5 treated with or without 10 μM MG132 with the indicated antibodies. The density of multiple experiments were quantified (bottom) (n = 3, each). (D) Western blotting of lysates from HEK293T cells transfected with negative control siRNA (siCont) or siRNA targeting to CUL3 (siCUL3) followed by transfection of pcDNA3.1-myc or pcDNA3.1-myc-hARMC5 together with pcDNA3.1-FLAG-Srebf1 with indicated antibodies. (E) Cell-based ubiquitination assay of the HEK293T cells transfected with pcDNA3.1-FLAG-Srebf1 together with pcDNA3.1-myc (–) or pcDNA3.1-myc-mArmc5 (+), followed by treatment with or without MG132, using the indicated antibody. The density of anti-HA relative to anti-FLAG were quantified (right) (n = 4, each). *P < 0.05, **P < 0.01, ***P < 0.001 by Tukey-Kramer test. See complete unedited blots in the supplemental material.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts